Vactosertib,1352610-25-3

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Vactosertib Hydrochloride

CAS No. : 1352610-25-3

MCE 国际站：Vactosertib Hydrochloride

产品活性：Vactosertib Hydrochloride (EW-7197 Hydrochloride) 是一种有效的，具有口服活性且具有 ATP 竞争性激活素受体样激酶 5 (ALK5) 抑制剂，IC₅₀ 为 12.9 nM。Vactosertib Hydrochloride 还以纳摩尔浓度抑制 ALK2 和 ALK4 (IC₅₀ 为17.3 nM)。Vactosertib Hydrochloride 具有强大的抗转移活性和抗癌作用。

研究领域：TGF-beta/Smad

作用靶点：TGF-β Receptor

In Vitro: Vactosertib (10-1000 nM; 30 minutes; 4T1 cells) treatment blocks the TGFβ-induced phosphorylation of Smad2 or Smad3 in a dose-dependent manner in 4T1 cells.
Vactosertib suppresses the TGFβ-induced nuclear translocation of Smad2/3 in 4T1 cells and MCF10A cells. The IC₅₀ value of Vactosertib on pSmad3 in 4T1 cells is 10-30 nM.
Vactosertib abrogates TGFb1-induced tumor cell migration and invasion.
TGFβ1 downregulated the mRNA level of CDH1 and upregulated the mRNA levels of FN1, HMGA2 (high-mobility group AT-hook 2), SNAI1, and SNAI2 (Snail family zinc finger 1 and 2, respectively). Moreover, Vactosertib abolishes the TGFβ1-induced effects on genes related to epithelial-to-mesenchymal transition (EMT).

In Vivo: Vactosertib (40 mg/kg; intraperitoneal injection; every other day; for 10 weeks; MMTV/c-Neu female mice) treatment inhibits Smad/TGFβ signaling, cell migration, invasion, and lung metastasis in MMTV/c-Neu mice.
Vactosertib also inhibits the epithelial-to-mesenchymal transition (EMT) in both TGFβ-treated breast cancer cells and 4T1 orthotopic-grafted mice. Furthermore, Vactosertib enhances cytotoxic T lymphocyte activity in 4T1 orthotopic-grafted mice and increased the survival time of 4T1-Luc and 4T1 breast tumor-bearing mice.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  TGF-beta/Smad Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Osteogenesis Compound Library  |  Cancer Stem Cells Compound Library  |  Heterocyclic Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Cytokine Inhibitors Library  |  SB-431542  |  Dorsomorphin  |  A 83-01  |  Galunisertib  |  LDN193189  |  RepSox  |  LY2109761  |  DMH-1  |  SB 525334  |  Vactosertib  |  BMP signaling agonist sb4  |  LY-364947  |  SB-505124  |  LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)  |  GW788388  |  ITD-1  |  LDN-212854  |  LY3200882  |  Bimagrumab  |  ML347  |  SD-208  |  K02288  |  Fresolimumab  |  IN-1130  |  LDN-214117  |  R-268712

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds